Excessive screen time raises heart disease risk: study
The study tracked the screen consumption and sleep habits of more than 1,000 10-year and 18-year-olds, with researchers examining the relationship between screen time and cardiometabolic risk factors.
'Children and young adults who spend excessive hours glued to screens and electronic devices may have higher risks for cardiometabolic diseases, such as high blood pressure, high cholesterol and insulin resistance,' said the study published in the Journal of the American Heart Association. Subsequently they face a higher risk of developing cardiovasculardiseases or diabetes, the researchers found.
The analysis revealed that eachadditional hour of daily screentime increases the risk of disease.
'This means a child with threeextra hours of screen time a daywould have roughly a quarter tohalf a standard-deviation higherrisk than their peers,' lead authorDavid Horner, a researcher at theUniversity of Copenhagen in Denmark, said in a statement.
'Multiply that across a wholepopulation of children, and you'relooking at a meaningful shift inearly cardiometabolic risk thatcould carry into adulthood,'Horner added.
Researchers are divided onthe potential harmful effects ofscreens on children and adolescents, but the majority agree thatyounger populations are more atrisk compared to adults.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Tribune
6 days ago
- Daily Tribune
Excessive screen time raises heart disease risk: study
Children who spend too much time in front of screens, whether phones or TVs, have an increased risk of heart and metabolic disease, according to a Danish study published yesterday. The study tracked the screen consumption and sleep habits of more than 1,000 10-year and 18-year-olds, with researchers examining the relationship between screen time and cardiometabolic risk factors. 'Children and young adults who spend excessive hours glued to screens and electronic devices may have higher risks for cardiometabolic diseases, such as high blood pressure, high cholesterol and insulin resistance,' said the study published in the Journal of the American Heart Association. Subsequently they face a higher risk of developing cardiovasculardiseases or diabetes, the researchers found. The analysis revealed that eachadditional hour of daily screentime increases the risk of disease. 'This means a child with threeextra hours of screen time a daywould have roughly a quarter tohalf a standard-deviation higherrisk than their peers,' lead authorDavid Horner, a researcher at theUniversity of Copenhagen in Denmark, said in a statement. 'Multiply that across a wholepopulation of children, and you'relooking at a meaningful shift inearly cardiometabolic risk thatcould carry into adulthood,'Horner added. Researchers are divided onthe potential harmful effects ofscreens on children and adolescents, but the majority agree thatyounger populations are more atrisk compared to adults.
Daily Tribune
23-07-2025
- Daily Tribune
Eating Avocados Twice a Week Linked to Lower Risk of Heart Disease, New Study Finds
A recent study published in the Journal of the American Heart Association has found that eating at least two servings of avocado per week may significantly lower the risk of heart disease and stroke. Researchers believe this is the first large-scale, long-term study to show a strong connection between high avocado consumption and reduced risk of cardiovascular events such as coronary heart disease and stroke. Avocados are rich in dietary fiber and heart-healthy fats—especially monounsaturated fats—which are known to support cardiovascular health. Previous clinical trials have also shown that avocados can help reduce risk factors like high cholesterol. 'This is particularly noteworthy given how avocado consumption has increased sharply in the U.S. over the past 20 years,' said Dr. Lorena S. Pacheco, a nutrition expert at Harvard University. 'According to data from the U.S. Department of Agriculture, more people are making avocados a regular part of their diet.' The researchers followed over 68,000 women (ages 30–55) from the Nurses' Health Study and more than 41,000 men (ages 40–75) from the Health Professionals Follow-Up Study for over 30 years. All participants were free of cancer, coronary heart disease, and stroke at the start of the study. During the study, the team documented 9,185 cases of coronary heart disease and 5,290 strokes. Participants filled out food frequency questionnaires at the beginning of the study and every four years after that. Avocado intake was measured by asking how often and how much they consumed. One serving was defined as half an avocado or half a cup of avocado. The results showed that those who ate two or more servings per week had a significantly lower risk of heart-related illnesses compared to those who rarely or never ate avocados.
Trade Arabia
01-05-2025
- Trade Arabia
Novo Nordisk, Ebn Sina Medical launch Wegovy in Qatar
Ebn Sina Medical, a subsidiary of Aamal Company and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish global healthcare company, have announced the availability of Wegovy (Semaglutide 2.4mg) in Qatar. The event was attended by Anders Bjørn Hansen, the Ambassador of Denmark to the UAE and Qatar, Aamal Company CEO Rashid Al Mansoori, Manvendra Singh, General Manager of Novo Nordisk Qatar and Dr Nayla Mansour, Commercial Director of Ebn Sina Medical. Wegovy® (Semaglutide 2.4mg), the once-weekly GLP-1 receptor agonist (GLP-1RA) indicated for chronic weight management in adults and adolescents ages 12 years and above, is now available in Qatar. Obesity has emerged as a significant global epidemic, affecting approximately 1 billion individuals world-wide. Obesity in the Gulf is rapidly unfolding with the highest rates globally. In Qatar, the obesity crisis is particularly severe, the current prevalence of obesity (body mass index [BMI] ≥ 30 kg/m2) amongst adults in Qatar is estimated to be 41% with a notably higher prevalence amongst women (46%) and, nearly 76% of individuals in Qatar are classified as overweight. This places Qatar among the top 10 highest obesity rates in the world, a statement said quoting statisitics. The high rates of obesity and overweight in Qatar are linked to the high-country overall rates of related chronic conditions such as pre-diabetes, diabetes and cardiovascular diseases (CVDs). The active ingredient in Wegovy®, Semaglutide 2.4 mg, works by reducing hunger and increasing the feeling of fullness. Wegovy is indicated as adjunct to reduced calorie intake and increased physical activity for weight management, including weight loss and weight maintenance in adults with obesity (BMI ≥ 30 kg/m2) or with overweight (BMI ≥ 27 kg/m2) in the presence of at least one weight-related comorbidity. As per clinical research, Wegovy on top of diet and exercise delivers 17% mean weight loss sustained over 2 years with one third of patients having a reduction of at least 20% body weight loss. Semaglutide 2.4 mg demonstrated significant improvements in other cardiometabolic risk factors such as: waist circumference, blood pressure, lipid profile, Glycemic parameters & C-reactive protein, the statement said. The SELECT clinical study including 17,604 adults with a BMI ≥27 kg/m2 demonstrated that Semaglutide 2.4 mg resulted in a statistically significant 20% risk reduction in Major Adverse Cardiovascular Events (MACE) in people with overweight or obesity and established CVD, without T2DM1, it said. Besides its indication in adults, Wegovy® is also approved as the first and only once weekly GLP-1 receptor agonist (GLP-1RA) for chronic weight management in adolescents with obesity from the age of 12 years. This innovation may help transform the medical management of adolescent obesity in Qatar, where nearly 20% of children and adolescents are affected, it noted. - TradeArabia News Service
